Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Vltava Fund's investment thesis on Novo Nordisk ($NVO) — Q1 2026 | Buyside Digest

All Pitches

View Letter Analysis

$NVONASDAQNovo Nordisk

BEAR

Vltava Fund—NVO

Fund Letter

Q1 2026

Published April 1, 2026

View Fund Profile

$45.77USD

-1.8% vs last month

$36.98Pitched

+23.8% since pitch

Market Cap$202.3B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

The fund decided to completely sell its position in Novo Nordisk after experiencing a deterioration in the company's multi-year financial outlook. Despite buying the...

— Daniel Gladiš

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $NVO, and what else Vltava Fund is buying.

Other pitches on $NVO

Other investors who've written on Novo Nordisk

The Heptagon Future Trends FundBULL

Pitched Mar 31, 2026

Novo Nordisk experienced short-term headwinds as its recent financial guidance failed to meet consensus estimates. However, the manager...

View all $NVO pitches →